CM
FBRX icon

Caption Management’s Forte Biosciences FBRX Stock Holding History

Caption Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-267
Closed -$66K – 890
2019
Q3 		$66K Hold
267
– – ﹤0.01% 645
2019
Q2 		$668K Buy
+267
New +$792K 0.03% 439

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caption Management's FBRX Position: Q4 2019 in Review

Caption Management sold out of Forte Biosciences (FBRX) in Q4 2019, closing a stake of 256 shares — an estimated $64K sold.

Caption Management first reported a position in FBRX in Q4 2018 and held it in 4 quarters. The position peaked at $852K in Q2 2019. 51 funds tracked by Wall St. Rank hold FBRX as of Q4 2019.

  • Caption Management reported no remaining Forte Biosciences position as of Q4 2019 after selling out during the quarter.
  • Caption Management sold 256 Forte Biosciences shares in Q4 2019, an estimated $64K.
  • Caption Management first reported a position in Forte Biosciences in Q4 2018 and held it in 4 quarters.
  • Caption Management's Forte Biosciences position peaked at $852K in Q2 2019.
  • 51 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2019.

Based on Caption Management's 13F filing for Q4 2019, filed 13 Feb 2020.